ライフサイエンスコーパス: taxane

1 er previously treated with trastuzumab and a taxane.

2 er previously treated with trastuzumab and a taxane.

3 a proposed biosimilar or trastuzumab plus a taxane.

4 4 mg/kg weekly and a further 80 to receive a taxane.

5 tigen (PSA) decline by cycle 4 (C4) switched taxane.

6 ar (n = 230) or trastuzumab (n = 228) with a taxane.

7 C) who previously received trastuzumab and a taxane.

8 retherapy AR-V7-positive CTCs treated with a taxane.

9 ogen receptor signaling (ARS) inhibitor or a taxane.

10 rapy were administered concurrently with the taxane.

11 nes, including a monoacetylated dioxygenated taxane.

12 er previously treated with trastuzumab and a taxane.

13 er previous treatment with trastuzumab and a taxane.

14 of clinical benefit in patients treated with taxanes.

15 67.5% received previous anthracyclines plus taxanes.

16 onse and outcomes between ARS inhibitors and taxanes.

17 d monotherapy in 2 L, of whom 69.0% received taxanes.

18 is associated with decreased sensitivity to taxanes.

19 t target microtubule disassembly, similar to taxanes.

20 ncer is resistance to chemotherapies such as taxanes.

21 neurotoxic effects of current agents such as taxanes.

22 with MBC pretreated with anthracyclines and taxanes.

23 h androgen receptor signaling inhibitors and taxanes.

24 uic acid (PCA) did not alter cytotoxicity of taxanes.

25 racycline-based chemotherapy with or without taxanes.

26 th abiraterone or enzalutamide compared with taxanes.

27 In the control arm, 29.6% only received taxanes (0.5% of N0 patients).

28 sequential or combination anthracycline and taxane (106 patients in the scalp cooling group and 16 i

29 two important genes of this pathway, namely taxane 13alpha-hydroxylase (T13alphaH) and 10-deacetylba

30 /= 30% PSA declines by C4 and did not switch taxane, 15 patients (24.6%) who did not achieve >/= 30%

31 Of patients switching taxane, 46.7% subsequently achieved >/= 50% PSA decrease

32 se (pCR) from standard-of-care anthracycline/taxane (ACT) chemotherapy.

33 nt samples to identify in vivo mechanisms of taxane action and resistance.

34 e to routinely used cytotoxic drugs, such as taxanes, activated a metabolic switch that conferred tol

35 lationship between BRCA1 (B1) expression and taxane activity remains unclear.

36 sitive disease, sequential anthracycline and taxanes administered concurrently with trastuzumab or do

37 omes by enhancing mitotic defects induced by taxanes alone.

38 erative (neoadjuvant) breast cancer therapy, taxanes and anthracyclines, elicit tumour-derived EVs wi

39 rone therapy, whereas in AR-V7-negative men, taxanes and enzalutamide or abiraterone may have compara

40 e transporters in the hepatic elimination of taxanes and indicate that this process can be inhibited

41 emical syntheses of eudesmanes, germacrenes, taxanes and ingenanes have all benefited from a strategy

42 inum agent, followed by later treatment with taxanes and irinotecan, provides some benefit.

43 l representative agents in clinical use, the taxanes and the vinca alkaloids, come from terrestrial s

44 rotubule-targeting agents (MTA), such as the taxanes and vinca alkaloids, are used to treat a variety

45 e vs 78 [70%] of 111 patients treated with a taxane), and similar incidences of adverse events leadin

46 achieve >/= 30% PSA declines by C4 switched taxane, and 13 patients (21.3%) discontinued therapy bef

47 in to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete

48 previously treated with an anthracycline, a taxane, and capecitabine (and two to five previous regim

49 rdiotoxic effects (including anthracyclines, taxanes, and cyclophosphamide) were defined as time-depe

50 ents in the current report received standard taxane- and anthracycline-based neoadjuvant therapy with

51 led to potent efficacy and survival in both taxane- and docetaxel-resistant in vivo anticancer mouse

52 breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scal

53 given in a specific order, a combination of taxanes, anthracyclines, and inhibitors of glucose-6-pho

54 Taxane antineoplastic agents are extensively taken up in

55 zumab and lapatinib (advanced setting) and a taxane (any setting) and with progression on two or more

56 In AR-V7-positive men, taxanes appear to be more efficacious than enzalutamide

57 ved the highest reported titer of oxygenated taxanes ( approximately 570 +/- 45 mg/L) in E. coli.

58 Taxanes are a family of natural products with a broad sp

59 Taxanes are a standard of care therapy in castration-res

60 The taxanes are effective microtubule-stabilizing chemothera

61 Responses to platinum-etoposide and taxanes are frequent, but checkpoint inhibitors yielded

62 The taxanes are important components of prostate cancer chem

63 chanisms underlying the clinical activity of taxanes are poorly understood.

64 improve pCR, sequencing chemotherapy so that taxanes are received before anthracyclines could improve

65 Taxanes are the mainstay of treatment in triple-negative

66 Taxanes are the only chemotherapies used to treat patien

67 first-line treatment, which often includes a taxane, are still in need of more effective combination

68 l utility of combining AURKA inhibitors with taxanes as a therapeutic strategy for the treatment of E

69 lly) on day 1 (except for patients receiving taxanes as part of moderately emetogenic chemotherapy, w

70 We targeted Taxol, the flagship taxane, as the upper limit of chemical complexity and em

71 and anti-tumor effect with palbociclib plus taxanes at clinically achievable doses in multiple SqCLC

72 ung and other cancers currently treated with taxane based chemotherapy as standard of care.

73 addition of gemcitabine to anthracycline and taxane-based adjuvant chemotherapy at this dose and sche

74 Taxane-based anticancer treatments lead to the stabiliza

75 debris generated by first-line platinum- and taxane-based chemotherapy accelerates tumor progression

76 of trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not result in long-term w

77 n androgen receptor-directed therapy and one taxane-based chemotherapy for mCRPC.

78 chieve a pCR after neoadjuvant anthracycline-taxane-based chemotherapy plus anti-HER2 treatment, even

79 aive) depending on whether they had received taxane-based chemotherapy prior to (177)Lu-PRLT.

80 y) with placebo in women undergoing adjuvant taxane-based chemotherapy was conducted.

81 ted to have a poor response to anthracycline/taxane-based chemotherapy.

82 based chemotherapy and 64% (n = 91) received taxane-based chemotherapy.

83 ripheral neuropathy in patients treated with taxane-based chemotherapy.

84 ) include anthracycline-cyclophosphamide and taxane-based chemotherapy.

85 e addition of platinum to anthracycline- and taxane-based chemotherapy.

86 assigned them to adjuvant anthracycline plus taxane-based combinations with either 9 weeks or 1 year

87 cell-permeable probes outperform commercial taxane-based probes and enable direct visualization of t

88 east cancer and other malignancies, existing taxane-based therapies including paclitaxel and the seco

89 oss of PI3K-C2alpha increases sensitivity to taxane-based therapy in pre-clinical models and in neoad

90 BC who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive e

91 uzumab (in the context of anthracycline- and taxane-based therapy) continues to have a favorable bene

92 fication factors included institution, prior taxane-based therapy, involved axillary lymph nodes, and

93 Anthracycline- and taxane-based three-drug chemotherapy regimens have prove

94 Receipt of a taxane before anthracycline was associated with improved

95 agent NACT with (n = 49) or without (n = 13) taxanes between 2008 and 2011.

96 tubules were stabilized by epothilone at the taxane binding pocket.

97 n the estrogen receptor and the beta-tubulin taxane binding pocket.

98 P3 levels sensitize tumors to the effects of taxanes but not DNA-damaging agents.

99 ment of cancer cells with PI3K inhibitors or taxane causes FOXO1 localization in the nucleus, increas

100 Cabazitaxel is a second-line taxane chemotherapeutic agent that provides additional s

101 led patients with metastatic CRPC initiating taxane chemotherapy (docetaxel or cabazitaxel) at a sing

102 trastuzumab or lapatinib in combination with taxane chemotherapy (paclitaxel or docetaxel) for 24 wee

103 insight into therapeutic cross-resistance to taxane chemotherapy and androgen deprivation therapy in

104 frequently develop therapeutic resistance to taxane chemotherapy and antiandrogens.

105 ion chemotherapy followed by three cycles of taxane chemotherapy and then locoregional radiotherapy.

106 gic acid has the potential to interfere with taxane chemotherapy by reducing tubulin polymerization w

107 Patients were classified as either taxane chemotherapy pretreated (T-pretreated) or naive (

108 ough the combination of surgery and platinum-taxane chemotherapy provide an effective treatment, drug

109 te cancer previously treated with one or two taxane chemotherapy regimens and with an Eastern Coopera

110 ABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adju

111 ated with better OS in patients treated with taxane chemotherapy.

112 is not associated with primary resistance to taxane chemotherapy.

113 -resistant prostate cancer progressing after taxane chemotherapy.

114 atinib or the combination plus anthracycline-taxane chemotherapy.

115 nd later phases of mCRPC grouped by previous taxane chemotherapy.

116 Docetaxel is a chemotherapeutic agent of the taxane class of drugs for the treatment of breast cancer

117 49 compared TC6 with several standard AC and taxane combination regimens.

118 aggressive disease treated with platinum and taxane combination therapy.

119 eir ability to fit 24 data sets for platinum-taxane combinations and 21 data sets for various other c

120 Clinical outcomes were superior with taxanes compared with enzalutamide or abiraterone therap

121 As representative members of taxanes containing five oxygen atoms, decinnamoyltaxinin

122 gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast

123 eater-TNBC, with prior anthracycline- and/or taxane-containing chemotherapy.

124 A metaanalysis of older trials comparing taxane-containing ICT to cisplatin and 5-fluorouracil is

125 llent performance status, anthracycline- and taxane-containing regimens are the standard of care.

126 -based regimens, including anthracycline and taxane-containing regimens, were associated with better

127 al administration of CDK4/6 inhibitors after taxanes cooperates to prevent cellular proliferation in

128 nduction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorou

129 The microtubule-binding taxanes, docetaxel and cabazitaxel, are administered int

130 weeks, starting concomitantly with the first taxane dose.

131 hat synchronized co-delivery of the platinum-taxane drug combination via single carrier to the same t

132 s that clinical response was associated with taxane drug-target engagement, evidenced by decreased pe

133 xpression were sensitive to temozolomide and taxane drugs.

134 Patients were re-exposed to taxanes either through desensitization, challenge, or re

135 ainst microtubule stabilizing agents such as taxanes, epothilone B (EpoB) has merit, especially in co

136 cal interest, including, but not limited to, taxanes, epothilones, statins, retinoids, di-/triterpene

137 enable a divergent synthetic approach to the taxane family of natural products?

138 ated to medicinal chemistry endeavors in the taxane family, as well as to the synthesis of other terp

139 taxadiene, the lowest oxidized member of the taxane family, followed by three site-selective allylic

140 o "nanocarrier" for PTX as a next-generation taxane for cancer.

141 Trastuzumab, pertuzumab, and taxane for first-line treatment and T-DM1 for second-lin

142 stuzumab or lapatinib, in combination with a taxane, from January 17, 2008, through December 1, 2011.

143 e [3%]), and neutropenia (three [3%]) in the taxane group.

144 a (43 [39%]), and anaemia (20 [18%]), in the taxane group.

145 ekly group and 15.4 months (9.2-18.1) in the taxane group.

146 ts with hypersensitivity reactions (HSRs) to taxanes has not been established.

147 ne; nab(R)-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and impro

148 for antimitotic chemotherapeutic drugs like taxanes, has implications for drug response and drug res

149 Anthracyclines and taxanes have been the standard neoadjuvant chemotherapie

150 Lipophilic drugs, such as taxanes, have a high affinity for adipose tissue and a r

151 N: Trastuzumab emtansine was not superior to taxane in patients with previously treated, HER2-positiv

152 osimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-pos

153 ansine 2.4 mg/kg weekly, and 37 to receive a taxane in the stage 1 part of the trial.

154 al inhibitors of SFK/Hck in combination with taxanes in a temporally constrained manner, where the ki

155 tion of the risk-benefit ratio of the use of taxanes in breast cancer.

156 domized trials that investigated the role of taxanes in ICT, compared with surgery or CRT alone.

157 can help inform the choice between ARSI and taxanes in mCRPC patients.

158 e mechanisms of sensitivity or resistance to taxanes in men with chemotherapy-naive, metastatic, cast

159 Despite the initial efficacy of taxanes in treating CRPC, all patients ultimately fail d

160 hetic consortium produced 33 mg/L oxygenated taxanes, including a monoacetylated dioxygenated taxane.

161 Trials investigating taxane inclusion in induction chemotherapy and trials of

162 In 26 CTC-evaluable patients, taxane-induced decrease in %ARNL (cycle 1 day 1 v cycle

163 cting splice variant ARv567 was sensitive to taxane-induced microtubule stabilization.

164 ermline variants associated with the risk of taxane-induced peripheral neuropathy in breast cancer pa

165 Taxane-induced shifts in %ARNL may serve as an early bio

166 l modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards

167 he nucleus to cooperate with tubulin towards taxane insensitivity.

168 2.4 mg/kg weekly) or physician's choice of a taxane (intravenous docetaxel 75 mg/m(2) every 3 weeks o

169 totoxic chemotherapy, especially platins and taxanes, is a widespread problem among cancer survivors

170 At an equitoxic dose of 50 mg taxane/kg, ephrin A2-targeted liposomal prodrug showed g

171 Ephrin A2-targeted taxane liposomes exhibited sub-nanomolar (0.69 nM) appar

172 s [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of pr

173 Combining NEK2 inhibitors with taxanes may be a viable approach for improving patient o

174 Despite widespread use of taxanes, mechanisms of action and resistance in vivo rem

175 who were receiving sequential anthracycline-taxane NACT between October 2008 and October 2012.

176 th the Food and Drug Administration-approved taxane nanoformulation (Abraxane).

177 uzumab administration with anthracycline and taxane neoadjuvant chemotherapy.

178 stratified by type of on-study chemotherapy (taxane or gemcitabine-carboplatin), PD-L1 expression at

179 ere beginning neurotoxic chemotherapy with a taxane or platinum agent were recruited from oncology cl

180 Chemotherapy with a neurotoxic taxane or platinum agent.

181 of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without

182 with CDK4/6 inhibitors after application of taxanes (or other chemotherapeutic compounds) strongly p

183 status, chemotherapy [with an anthracycline, taxane, or both], hormone receptor status [negative vs l

184 herapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.

185 eoadjuvant chemotherapy with anthracyclines, taxanes, or combination of the two.

186 cancer patients treated with anthracyclines, taxanes, or fluoropyrimidines.

187 e treatment regimens include anthracyclines, taxanes, or fluoropyrimidines.Significance: These findin

188 ster derivatives (tetraalkoxysilanes) of the taxanes paclitaxel (PTX) and docetaxel (DTX) [i.e., PTX-

189 The clinically and commercially successful taxanes, paclitaxel and docetaxel suffer from two major

190 f prodrug encapsulation (as high as 114 mol% taxane per mole phospholipid) and subsequent stability (

191 nel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-dense treatment can be

192 ed in patients pretreated with fluorouracil, taxanes, platinum and/or eribulin, whereas the de novo m

193 Our data suggest that taxane-platinum combinations have a clinically beneficia

194 Taxane-platinum combinations have shown promising activi

195 istant relapse-free survival after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD A

196 (Nottingham-NeoACT; n=200), the MD Anderson taxane plus anthracycline-based neoadjuvant chemotherapy

197 plications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other effi

198 ad residual disease following treatment with taxanes plus an anthracycline, suggesting a role for thi

199 t have been proposed for epothilone A in the taxane pocket of beta-tubulin.

200 S in patients with trastuzumab-resistant and taxane-pretreated, HER2-positive, advanced breast cancer

201 The taxane prodrug was stabilized with extraliposomal citric

202 Oligo(lactic acid) ester taxane prodrugs are in pre-clinical development as novel

203 Notably, acyl and oligo(lactic acid) taxane prodrugs delivered by PEG-b-PLA and PEG-b-PCL nan

204 d immunoliposomes incorporating pH-sensitive taxane prodrugs were developed for sustained delivery of

205 apies that can be combined with the platinum-taxane regimen and overcome platinum resistance in high-

206 response toward two different anthracycline-taxane regimens; thus, highlighting the prospective for

207 the initial HSR and skin testing for guiding taxane reintroduction in patients with an HSR to these a

208 of the initial HSR and skin testing to guide taxane reintroduction is safe and allows a significant n

209 Data on 164 patients treated for a taxane-related HSR from April 2011 to August 2014 at the

210 ciated with survival showed superior OS with taxanes relative to ARS inhibitors when AR-V7-positive C

211 MR imaging-detectable effects of taxanes represent a combination of specific antimitotic

212 nding the mechanisms underlying platinum and taxane resistance in ovarian cancer.

213 itoring of patients with BRCA2 mutations for taxane resistance is warranted.

214 eta-tubulin and overcome clinically relevant taxane resistance mechanisms.

215 The molecular basis of clinical taxane resistance remains poorly understood.

216 is a therapeutically targetable mediator of taxane resistance that can be leveraged to improve respo

217 tion of IGF2 as a mechanism that can mediate taxane resistance through activation of IGF1/insulin rec

218 FOXM1 has been implicated in taxane resistance, but the molecular mechanism involved

219 hile sustained LIN9 is necessary to maintain taxane resistance, there are no inhibitors that directly

220 cers, malignancies that typically succumb to taxane resistance.

221 LIN9 is further elevated with acquisition of taxane resistance.

222 ible to PTX-induced stabilization conferring taxane resistance.

223 owing that low B1 expression correlated with taxane resistance.

224 otubules and overcome multiple mechanisms of taxane resistance.

225 ibitor of LIMK may offer a strategy to treat taxane-resistant breast tumors and metastases.

226 ose-response profile in taxane-sensitive and taxane-resistant cancer cell models, diminished risk of

227 may provide a therapeutic strategy to treat taxane-resistant cancers.

228 ntrosome separation that is also elevated in taxane-resistant cells.

229 Its activity against taxane-resistant xenografts makes it a potential drug ca

230 ith two distinct small molecules potentiated taxane response in multiple in vivo models of TNBC, incl

231 also suggest an effect of cGAS expression on taxane response.

232 on analysis of breast cancers indicates that taxane responses correlate positively with Myc and negat

233 rastuzumab emtansine (2.4 mg/kg weekly) or a taxane (same regimen as above).

234 ctional Assessment of Cancer Therapy (FACT) -Taxane scale at 12 weeks.

235 xhibits an improved dose-response profile in taxane-sensitive and taxane-resistant cancer cell models

236 ression with a global BET inhibitor restored taxane sensitivity by inducing mitotic progression error

237 e, whose expression has been correlated with taxane sensitivity in many solid tumors including non-sm

238 r protein, thereby resulting in differential taxane sensitivity in vitro and in vivo.

239 gesting a role for this kinase in modulating taxane sensitivity.

240 n for the ability of BH3 mimetics to enhance taxane sensitivity.

241 ho had previously received trastuzumab and a taxane, separately or in combination, the first ADC to r

242 via cellular and biochemical assays confirms taxane site interaction, microtubule stabilization, and

243 To discover taxane site modulators, we employ a computational bindin

244 activity is mediated by interaction with the taxane site of beta-tubulin, leading to microtubule stab

245 , B2 may be more adaptable to changes in the taxane site relative to DDM that could account for its f

246 EM) reconstructions of MTs stabilized by the taxane-site binders Taxol and zampanolide, and by peloru

247 orters is strongly dependent on the selected taxane solubilizer.

248 ork necessary to access even higher oxidized taxanes such as 1 in a more practical fashion, thus empo

249 import that affect the antitumor efficacy of taxanes, suggesting a mechanistic rationale to customize

250 trial evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarker

251 Conclusion The early taxane switch strategy was associated with improved PSA

252 These findings indicate that taxanes target both mitotic and interphase cells in vivo

253 ctivity of TC relative to AC regimens with a taxane (TaxAC) is unknown.

254 method here for two platinum compounds and a taxane that otherwise bound irreversibly to dialysis mem

255 on of CDK4/6 inhibitors with gemcitabine and taxanes that are employed in the treatment of PDAC.

256 This includes taxanes that are used routinely in clinics to treat pros

257 -positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar co

258 entify phase II and III trials that included taxane therapy from 1999 to 2011.

259 ding trastuzumab and lapatinib, and previous taxane therapy in any setting, were randomly assigned (i

260 Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a s

261 that is associated with superior survival on taxane therapy over ARS-directed therapy in a clinical p

262 180 HGS-OvCa patients treated with platinum-taxane therapy revealed 61 transcript isoforms that char

263 eatment type (androgen signaling inhibitor v taxane therapy) were observed (CSS adjusted P = .014; PF

264 Patients were stratified by previous taxane therapy, visceral metastasis, hormone receptor st

265 breast carcinoma who had previously received taxane therapy.

266 uded because they were not initiating ARS or taxane therapy; and 18 were excluded for processing time

267 cal benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant

268 s exhibit potent combinatorial activity with taxanes to inhibit tumor growth.

269 Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers.

270 One of the striking physical features of taxane-treated cells is the localization of their microt

271 cells with stabilized microtubules, such as taxane-treated cells.

272 PSA PFS and PFS were significantly longer in taxane-treated men (HR, 0.19 [95% CI, 0.07-0.52] for PSA

273 tatistical plan required a sample size of 36 taxane-treated men.

274 Of 37 taxane-treated patients enrolled, 17 (46%) had detectabl

275 itive patients, PSA responses were higher in taxane-treated vs enzalutamide- or abiraterone-treated m

276 mg/kg weekly and 8.6 months (7.1-11.2) with taxane treatment (hazard ratio 1.15, 95% CI 0.87-1.51, o

277 gest that microtubule bundling after initial taxane treatment may be a predictive biomarker for clini

278 The combination of RSPO3 inhibition and taxane treatment provides an approach to effectively tar

279 re the kinase inhibitor is administered post taxane treatment, but not when co-administered, markedly

280 continuation (31 [14%] vs 15 [14%]) than did taxane treatment.

281 ls and is associated with poorer response to taxane treatment.

282 riptional activity of ARv7 was unaffected by taxane treatment.

283 role in microtubule biology and response to taxane treatment.

284 ng response phenotypes for anthracycline and taxane, two common anticancer agents use in clinics.

285 terone or enzalutamide use ( P = .03), prior taxane use ( P = .02), and Eastern Cooperative Oncology

286 ine pain score of 4 to 6 v 7 to 10 and prior taxane use).

287 for the baseline score, osteoarthritis, and taxane use, adjusted 12-week BPI-SF scores did not diffe

288 Randomisation was stratified by previous taxane use, liver metastases, and PD-L1 expression on tu

289 prior abiraterone or enzalutamide use, prior taxane use, presence of visceral metastases, and Eastern

290 ase (MK-1775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented.

291 s (positive or negative) and treatment type (taxane vs enzalutamide or abiraterone).

292 Cabazitaxel, a next generation taxane, was the first Food and Drug Administration-appro

293 progressed on trastuzumab, pertuzumab, and a taxane were treated with T-DM1 at 3.6 mg/kg intravenousl

294 after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged

295 d use of chemotherapeutic agents such as the taxanes, which cause severe gastrointestinal mucositis.

296 s was completely reversed in the presence of taxanes, which reconciles incompatible observations in c

297 oxidation enabled access to a wider range of taxanes, which was demonstrated by the two-phase synthes

298 ics developed for the two-phase synthesis of taxanes, whose lessons can be potentially extrapolated t

299 that the in vitro and in vivo interaction of taxanes with OATP1B transporters is affected by the choi

300 transformation, both platinum-etoposide and taxanes yielded high response rates, but none of 17 pati